Cancer tissue of origin constrains the growth and metabolism of metastases.

Autor: Sivanand S; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA., Gultekin Y; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA., Winter PS; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA., Vermeulen SY; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA., Tchourine KM; Department of Systems Biology, Columbia University Medical Center, New York, NY, USA., Abbott KL; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Danai LV; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biochemistry and Molecular Biology, University of Massachusetts Amherst, Amherst, MA, USA., Gourgue F; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA., Do BT; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA., Crowder K; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Kunchok T; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Lau AN; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA., Darnell AM; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA., Jefferson A; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.; Whitehead Institute for Biomedical Research, Cambridge, MA, USA., Morita S; Edwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Duda DG; Edwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Henning N; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Preclinical Imaging and Testing Facility, Massachusetts Institute of Technology, Cambridge, MA, USA., Spanoudaki V; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Preclinical Imaging and Testing Facility, Massachusetts Institute of Technology, Cambridge, MA, USA., Maiorino L; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Irvine DJ; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA.; Ragon Institute of MGH, MITnd Harvard, Cambridge, MA, USA., Yilmaz OH; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital and Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA., Lewis CA; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.; Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA., Vitkup D; Department of Systems Biology, Columbia University Medical Center, New York, NY, USA.; Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, USA., Shalek AK; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Ragon Institute of MGH, MITnd Harvard, Cambridge, MA, USA.; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA., Vander Heiden MG; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. mvh@mit.edu.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. mvh@mit.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. mvh@mit.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. mvh@mit.edu.

Publikováno v: Nature metabolism [Nat Metab] 2024 Sep; Vol. 6 (9), pp. 1668-1681. Date of Electronic Publication: 2024 Aug 19.

Tumor apelin and obesity are associated with reduced neoadjuvant chemotherapy response in a cohort of breast cancer patients.

Autor: Gourgue F; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life Sciences and BIOtechnology), UCLouvain, Université catholique de Louvain, Brussels, Belgium., Derouane F; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium., van Marcke C; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium., Villar E; Breast Clinic, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium., Dano H; Department of Pathology, Cliniques Universitaires St Luc, Brussels, Belgium., Desmet L; Statistical Methodology and Computing Service, LIDAM, Université Catholique de Louvain, Brussels, Belgium., Bouzin C; Imaging Platform 2IP, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Université catholique de Louvain, Brussels, Belgium., Duhoux FP; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc and Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium. francois.duhoux@uclouvain.be., Cani PD; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life Sciences and BIOtechnology), UCLouvain, Université catholique de Louvain, Brussels, Belgium. patrice.cani@uclouvain.be., Jordan BF; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium. benedicte.jordan@uclouvain.be.

Publikováno v: Scientific reports [Sci Rep] 2021 May 10; Vol. 11 (1), pp. 9922. Date of Electronic Publication: 2021 May 10.

Obesity and triple-negative-breast-cancer: Is apelin a new key target?

Autor: Gourgue F; Metabolism & Nutrition Research Group, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life sciences and BIOtechnology), UCLouvain, Université catholique de Louvain, Brussels, Belgium.; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium., Mignion L; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium., Van Hul M; Metabolism & Nutrition Research Group, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life sciences and BIOtechnology), UCLouvain, Université catholique de Louvain, Brussels, Belgium., Dehaen N; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium., Bastien E; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique, UCLouvain, Université catholique de Louvain, Brussels, Belgium., Payen V; Pole of Pediatrics, Institut de Recherche Expérimentale et Clinique, UCLouvain, Université catholique de Louvain, Brussels, Belgium., Leroy B; Laboratory of Proteomics and Microbiology, MS-Quanta Platform, Research Institute for Biosciences, University of Mons, Mons, Belgium., Joudiou N; Nuclear and Electron Spin Technologies (NEST) Platform, Louvain Drug Research Institute (LDRI), UCLouvain, Université catholique de Louvain, Brussels, Belgium., Vertommen D; de Duve Institute (DDUV), Université catholique de Louvain (UCLouvain), Brussels, Belgium., Bouzin C; Imaging platform 2IP, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Université catholique de Louvain, Brussels, Belgium., Delzenne N; Metabolism & Nutrition Research Group, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life sciences and BIOtechnology), UCLouvain, Université catholique de Louvain, Brussels, Belgium., Gallez B; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium., Feron O; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique, UCLouvain, Université catholique de Louvain, Brussels, Belgium., Jordan BF; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium., Cani PD; Metabolism & Nutrition Research Group, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life sciences and BIOtechnology), UCLouvain, Université catholique de Louvain, Brussels, Belgium.

Publikováno v: Journal of cellular and molecular medicine [J Cell Mol Med] 2020 Sep; Vol. 24 (17), pp. 10233-10244. Date of Electronic Publication: 2020 Jul 17.

Metabolic imaging using hyperpolarized ¹³ C-pyruvate to assess sensitivity to the B-Raf inhibitor vemurafenib in melanoma cells and xenografts.

Autor: Acciardo S; Biomedical Magnetic Resonance (REMA) Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium., Mignion L; Biomedical Magnetic Resonance (REMA) Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium.; Nuclear and Electron Spin Technologies (NEST) Platform, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium., Lacomblez E; Biomedical Magnetic Resonance (REMA) Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium., Schoonjans C; Biomedical Magnetic Resonance (REMA) Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium., Joudiou N; Nuclear and Electron Spin Technologies (NEST) Platform, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium., Gourgue F; Biomedical Magnetic Resonance (REMA) Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium., Bouzin C; Imaging platform 2IP, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium., Baurain JF; Molecular Imaging and Radiation Oncology (MIRO) Group, Institute de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium., Gallez B; Biomedical Magnetic Resonance (REMA) Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium.; Nuclear and Electron Spin Technologies (NEST) Platform, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium., Jordan BF; Biomedical Magnetic Resonance (REMA) Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium.; Nuclear and Electron Spin Technologies (NEST) Platform, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium.

Publikováno v: Journal of cellular and molecular medicine [J Cell Mol Med] 2020 Jan; Vol. 24 (2), pp. 1934-1944. Date of Electronic Publication: 2019 Dec 13.

Dynamic Changes of the Gut Microbiota and Its Functional Metagenomic Potential during the Development of Non-Small Cell Lung Cancer.

Autor: Feng, Cuijiao^1,2,3 (AUTHOR) 18829285357@163.com, Li, Na^1,2,3 (AUTHOR) 18004899551@163.com, Gao, Guangqi^1,2,3 (AUTHOR) guangqigao@163.com, He, Qiuwen^1,2,3 (AUTHOR) heidyww@163.com, Kwok, Lai-Yu^1,2,3 (AUTHOR) kwok_ly@yahoo.com, Zhang, Heping^1,2,3 (AUTHOR) hepingdd@vip.sina.com

Publikováno v: International Journal of Molecular Sciences. Apr2024, Vol. 25 Issue 7, p3768. 20p.